Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tucidinostat - HUYA Bioscience International

Drug Profile

Tucidinostat - HUYA Bioscience International

Alternative Names: Chidamide; CS-055; Epidaza; HBI-8000; Hiyasta

Latest Information Update: 06 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chipscreen Biosciences
  • Developer Bristol-Myers Squibb; Chipscreen Biosciences; GNT Biotech and Medicals Corporation; Guangxi Center for Disease Control and Prevention; HUYA Bioscience International; Meiji Seika Pharma; Zhejiang University
  • Class Acrylamides; Aminopyridines; Antineoplastics; Antivirals; Benzamides; Fluorinated hydrocarbons; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; HDAC1 protein inhibitors; HDAC10 protein inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors; Mitogen-activated protein kinase inhibitors; Proto oncogene protein c-akt inhibitors; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Adult T-cell leukaemia-lymphoma; Cutaneous T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adult T-cell leukaemia-lymphoma; Breast cancer; Peripheral T-cell lymphoma
  • Preregistration Diffuse large B cell lymphoma
  • Phase III Brain metastases; Malignant melanoma
  • Phase II/III Cutaneous T-cell lymphoma; HIV infections
  • Phase II Non-small cell lung cancer
  • Phase I/II Liver cancer; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 22 Feb 2024 Phase-II clinical trials in Peripheral T-cell lymphoma (Second-line therapy or greater) in Taiwan (PO) (NCT05833724)
  • 01 Feb 2024 Phase-III clinical trials in Peripheral T-cell lymphoma (Second-line therapy or greater, Combination therapy) in Japan (PO) (NCT06122389)
  • 30 Sep 2023 HUYA Bioscience International completes a phase I/II trial for Solid tumours (Combination therapy, Late-stage disease) in USA (PO,Tablet) (NCT02718066)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top